10x Genomics Dl Stock Current Ratio
| 1KJ Stock | EUR 12.61 0.07 0.56% |
10X GENOMICS DL fundamentals help investors to digest information that contributes to 10X GENOMICS's financial success or failures. It also enables traders to predict the movement of 10X Stock. The fundamental analysis module provides a way to measure 10X GENOMICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 10X GENOMICS stock.
10X |
10X GENOMICS DL Company Current Ratio Analysis
10X GENOMICS's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current 10X GENOMICS Current Ratio | 6.69 X |
Most of 10X GENOMICS's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 10X GENOMICS DL is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, 10X GENOMICS DL has a Current Ratio of 6.69 times. This is 129.9% higher than that of the Healthcare sector and significantly higher than that of the Health Information Services industry. The current ratio for all Germany stocks is notably lower than that of the firm.
10X Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 10X GENOMICS's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 10X GENOMICS could also be used in its relative valuation, which is a method of valuing 10X GENOMICS by comparing valuation metrics of similar companies.10X GENOMICS is rated third in current ratio category among its peers.
10X Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.28) % | |||
| Shares Outstanding | 95.6 M | |||
| Shares Owned By Insiders | 2.60 % | |||
| Shares Owned By Institutions | 99.56 % | |||
| Revenue | 503.71 M | |||
| Gross Profit | 416.4 M | |||
| EBITDA | (117.15 M) | |||
| Net Income | (504.02 M) | |||
| Cash And Equivalents | 621.96 M | |||
| Cash Per Share | 5.66 X | |||
| Total Debt | 70.82 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 6.69 X | |||
| Book Value Per Share | 6.78 X | |||
| Cash Flow From Operations | (219.4 M) | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 197.56 | |||
| Number Of Employees | 1.24 K | |||
| Beta | 1.67 | |||
| Market Capitalization | 5.23 B | |||
| Z Score | 43.8 |
About 10X GENOMICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X GENOMICS DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X GENOMICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X GENOMICS DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.